Sat, Dec 20, 2014, 6:47 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

  • lws2000 lws2000 Jan 23, 2012 8:12 PM Flag

    BOTOX demand drives AGN to new highs

    Allergan(AGN_) is a multi-specialty healthcare company. It has been given a buy rating by UBS Investment Research due to an improvement in its growth valuations. Earnings per share are expected to grow by more than 15% to 20%.
    The company's Botox line is highly sustainable and Allergan's pipeline is underappreciated at the moment. According to UBS, Allergan's growth profile would be a nice fit with other big pharmaceutical companies. UBS is expecting revenues of $1.4 billion by the end of 2012 and earnings per share of $1. The continued roll-out of Botox Migraine and Botox OAB NDO will be closely watched by UBS.
    Shares of the company are currently trading at $88 per share and are expected to reach a price target of $100, indicating a potential upside of 13.6%. Ken Fisher 's Fisher Asset Management had more than $350 million invested in Allergan at the end of September

212.63+0.45(+0.21%)Dec 19 4:01 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.